Global tuberculosis control: Lessons learnt and future prospects

Nature Reviews Microbiology

Volumn 10, Issue 6, 2012, Pages 407-416

  Lienhardt, Christian ^a   Glaziou, Philippe ^a   Uplekar, Mukund ^a   Lå ̈nnroth, Knut ^a   Getahun, Haileyesus ^a   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; BCG VACCINE; COTRIMOXAZOLE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BCG VACCINATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE POLICY; HEALTH SURVEY; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MASS IMMUNIZATION; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; REVIEW; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY; HIV INFECTIONS; HUMANS; TUBERCULOSIS; WORLD HEALTH;

EID: 84861199764     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2797     Document Type: Review

References (101)

1. Styblo, K. in Selected Papers, Vol. 24 (KNCV, 1991).
2. Lienhardt, C. From exposure to disease: the role of environmental factors in susceptibility to TB. Epidemiol. Rev. 23, 288-301 (2001).
3. Styblo, K. Overview and epidemiological assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev. Infect. Dis. 1, S339-S346 (1989).
4. Roelsgaard, E., Iversein, E. & Blocher, C. Tuberculosis in tropical Africa. Bull. World Health Organ. 30, 459-518 (1964).
5. Fine, P. E. M., Carneiro, I. A. M., Milstien, J. B. & Clements, C. J. Issues Relating to the Use of BCG in Immunisation Programmes. (WHO 1999).
6. Medical Research Council. Treatment of pulmonary tuberculosis with para-aminosalicylic acid and streptomycin: a preliminary report. BMJ 2, 1521 (1949).
7. Crofton, J. Chemotherapy of pulmonary tuberculosis. BMJ 1, 1610-1664 (1959).
8. Fox, W., Ellard, G. A. & Mitchison, D. A. Studies on the treatment of tubeculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant consequent publications. Int. J. Tuberc. Lung Dis. 10, S231-S279 (1999). (Pubitemid 29481843)
9. World Health Organization. Official Records of the World Health Organization, No(WHO, 1947).
10. Raviglione, M. D. & Pio, A. Evolution of WHO policies for tuberculosis control, 1948-200Lancet 359, 775-780 (2002). (Pubitemid 34215081)
11. Styblo, K. Recent advances in epidemiological research in tuberculosis. Adv. Tuberc.Res. 20, 1-63 (1980).
12. Styblo, K. & Meijer, J. Impact of vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 57, 17-43 (1976).
13. Mahler, H. The tuberculosis programme in the developing countries. Bull. Int. Union Tuberc. 37, 77-82 (1966).
14. Banerji, D. Tuberculosis: a problem of social planning in developing countries. Med. Care 3, 151-161 (1965).
15. WHO Expert Committee on Tuberculosis. Eighth Report. World Health Organization Technical Report Series No.
16. Berman, P. A. Health Sector Reform. Making health development sustainable. Health Policy 32, 13-29 (1995).
17. Miller, B. Health sector reform: scourge or salvation for TB control in developing countries? Int. J. Tuberc. Lung Dis. 4, 593-594 (2000). (Pubitemid 30463527)
18. Murray, C. J. L., Styblo, K. & Rouillon, A. Tuberculosis in developing countries: burden, intervention and cost. Bull. Int. Union Tuberc. Lung Dis. 65, 6-24 (1990). (Pubitemid 20163859)
19. Narain, J. P., Raviglione, M. C. & Kochi, A. HIVassociated tuberculosis in developing countries: epidemiology and strategies for prevention. Tubercle Lung Dis. 73, 311-321 (1992). (Pubitemid 23030567)
20. Raviglione, M. C., Snider, D. E. Jr & Kochi, A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 273, 220-226 (1995).
21. Bloom, B. & Murray, C. J. L. Tuberculosis: commentary on a re-emergent killer. Science 257, 1055-1064 (1992).
22. Enarson, D. A. Principles of IUATLD collaborative tuberculosis progammes. Bull. Int. Union Tuberc. Lung Dis. 66, 195-200 (1991).
23. Kochi, A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72, 1-6 (1991).
24. World Health Organization. Forty-fourth World Health Assembly: Resolutions and Decisions. Resolution WHA 44.8. WHA44/1991/REC/(WHO, 1991).
25. World Health Organisation. Framework for Effective Tuberculosis Control. WHO Tuberculosis Programme. (WHO, 1994).
26. Fox, W. The problem of self-administration of drugs, with particular reference to pulmonary tuberculosis. Tubercle 39, 269-274 (1958).
27. Tuberculosis Chemotherapy Center, Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull. World Health Organ. 21, 51-144 (1959).
28. Iseman, M. D., Cohn, D. L. & Sbarbaro, J. A. Directly oberved therapy: we can't afford not to do it. N. Engl. J. Med. 328, 576-578 (1993).
29. Raviglione, M. C., Dye, C., Schmidt, S. & Kochi. A. Assessment of worldwide tuberculosis control. Lancet 350, 624-629 (1997). (Pubitemid 27367796)
30. World Health Organisation. Global Tuberculosis Control. WHO Report 2001, Document WHO/CDS/TB/2001.287. (WHO, 2001).
31. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 364, 417-422 (2004).
32. Netto, E. M., Dye, C. & Raviglione, M.C. Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Int. J. Tuberc. Lung Dis. 3, 310-320 (1999). (Pubitemid 29166825)
33. Suarez, P. G. et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J. Infect. Dis. 184, 473-478 (2001). (Pubitemid 32718511)
34. World Health Organization. WHO Report 2007: Global Tuberculosis Control (Surveillance, Planning, Financing). (WHO
35. Dye, C., Watt, C. J. & Bleed, D. Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull. World Health Organ. 80, 437-444 (2002). (Pubitemid 34632819)
36. Zwarenstein, M., Schoeman, J. H., Vundule, C., Lombard, C. J. & Tatley, M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 352, 1340-1343 (1998). (Pubitemid 28510914)
37. De Cock, K. M. & Chaisson, R. E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int. J. Tuberc. Lung Dis. 3, 457-465 (1999). (Pubitemid 29260156)
38. Volminck, J., Matchaba, P. & Garner, P. Directly observed therapy and treatment adherence. Lancet 355, 1345-1350 (2000). (Pubitemid 30199013)
39. Walley, J. D., Khan, A. N., Newell, J. N. & Khan, M. H. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 357, 664-669 (2001). (Pubitemid 32206424)
40. Khan, M. A., Walley, J. D., Witter, S. N., Imran, A. & Safdar, N. Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly observed treatment. Health Policy Plan 17, 178-186 (2002). (Pubitemid 34587121)
41. Lienhardt, C. & Ogden, J. A. Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Trop. Med. Int. Hlth 9, 833- 841 (2004). (Pubitemid 38962012)
42. Pitchenik, A. E. & Fischl, M. A. Disseminated tuberculosis and the acquired immunodeficiency syndrome. Ann. Intern. Med. 98, 112 (1983). (Pubitemid 13217984)
43. Mann, J. et al. Association between HTLV-III LAV infection and tuberculosis in Zaire. JAMA 256, 346 (1986).
44. De Cock, K. M., Coulibaly, S. I. M. & Lucas, S. B. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 268, 1581-1587 (1992).
45. Getahun, H., Gunneberg, C., Granich, R. & Nunn, P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 50, S201-S207 (2010).
46. Harries, A. et al. Tuberculosis Lancet 375, 1906- 1919 (2010).
47. Godfrey-Faussett, P. et al. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull. World Health Organ. 80, 939-945 (2002). (Pubitemid 36056085)
48. World Health Organization. Report of a 'Lesson Learnt' Workshop on the Six ProTEST Pilot Projects in Malawi, South Africa and Zambia. (WHO, 2004).
49. Getahun, H., Scano, F. & Nunn, P. in Tuberculosis, a Comprehensive Clinical Reference. (eds Schaaf, H. S. & Zumla, A.) (Saunders Elsevier, 2009).
50. World Health Organization. Interim Policy on Collaborative TB/HIV Activities. (WHO, 2004).
51. Iseman, M. D. & Madsen, L. A. TB isolates resistant to the two principal drugs, isoniazid and rifampicin, or to those and additional drugs are referred to as multidrug-resistant strains. Clin. Chest Med. 10, 341 (1989).
52. Centers for Disease Control Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons- Florida and New York, 1988-199JAMA 266 1483-1485 1991
53. Edlin, B. R. et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326, 1514-1521 (1992).
54. Frieden, T. et al. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328, 521-526 (1993). (Pubitemid 23053827)
55. Pablos-Mendez, A. et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N. Eng. J. Med. 338, 1641-1649 (1998). (Pubitemid 28267908)
56. Cohn, D., Bustreo, F. & Raviglione, M. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin. Inf. Dis. 24, S121-S130 (1997).
57. World Health Organization. Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug-Resistant Tuberculosis MDR-TB (WHO, 2001).
58. Gupta, R. et al. Responding to market failure in tuberculosis control. Science 293, 1049-1051 (2001). (Pubitemid 32758067)
59. Gupta, R. et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop. Med. Intern. Health 7, 970-976 (2002). (Pubitemid 35356618)
60. World Health Organization. Global Tuberculosis Programme. Report of the Ad Hoc Committee on the Tuberculosis Epidemic. London, March 17-19, 1998. (WHO, 1998).
61. Kumaresan, J., Heitkamp, P., Smith, I & Billo, N. Global Partnership to Stop TB: A model of an effective public health partnership. Int. J. Tuberc. Lung Dis. 8, 120-129 (2004). (Pubitemid 38120716)
62. Kumaresan, J., Smith, I., Arnold, V. & Evans, P. The global TB drug facility. Innovative global procurement. Int. J. Tuberc. Lung Dis. 8, 130-138 (2004).
63. World Health Organization. Stop TB Initiative. Amsterdam. Declaration to Stop TB: a Call for Accelerated Action against Tuberculosis. (WHO 2000).
64. World Health Organization. Fifty-third World Health Assembly. Resolutions and Decisions. Resolution WHA 53.WHA53/2000/REC/. (WHO, 2000).
65. World Health Organization. The Global Plan to Stop Tuberculosis - Stop TB Partnership. WHO/CDS/STB/2001.16. (WHO, 2001).
66. Stop TB Partnership and WHO. Global Plan to Stop TB 2006-2015. Actions for Life-Towards a World Free of Tuberculosis. WHO/HTM/STB/2006.35. (WHO, 2006).
67. Brugha, R. & Walt, G. A global health fund: a leap of faith? BMJ 323, 152-154 (2001). (Pubitemid 32678394)
68. Brugha, R. et al. The Global Fund: managing great expectations. Lancet 364, 95-100 (2004). (Pubitemid 38968630)
69. Uplekar, M., Weil, D., Raviglione, M. C. in Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach (Informa Healthcare, 2006)
70. Dye, C. et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293, 2767- 2775 (2005). (Pubitemid 40965089)
71. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. (WHO, 2001).
72. World Health Organization. Report on the Meeting of the Second Ad-Hoc Committee on the TB Epidemic- Recommendations to Stop TB partners-Montreux, Switzerland, Sept. 2003. WHO/CDS/STB/2004.28. (WHO, 2004).
73. World Health Organization. Fifty-eighth World Health Assembly. WHA58/2005/REC/(WHO, 2005).
74. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO/HTM/TB/2006.36(WHO, 2006).
75. World Health Organization. Community Contribution to TB care: Practice and Policy. WHO/CDS/TB/2002.318. (WHO, 2002).
76. Achmat, Z. Science and social justice: the lessons of HIV/AIDS activism in the struggle to eradicate tuberculosis. Int. J. Tuberc. Lung Dis. 10, 1312-1317 (2006). (Pubitemid 44924584)
77. Harrington M. From HIV to tuberculosis and back again: a tale of activism in 2 pandemics. Clin. Infect. Dis. 50, S260-S266 (2010).
78. Lönnroth, K. et al. Public-private mix for implementation: what makes it work? Bull. World Health Organ. 82, 580-586 (2004). (Pubitemid 39108147)
79. Hopewell, P. C., Pai, M., Maher, D., Uplekar, M. & Raviglione, M. C. International standards for tuberculosis care. Lancet Infect. Dis. 6, 710-725 (2006). (Pubitemid 44740086)
80. World Health Organization. Practical Approach to Lung Health PALA Primary Health Care Strategy for the Integrated Management of Respiratory Conditions in People Five Years of Age or Over. WHO/HTM/TB/2005.35(WHO, 2005).
81. Raviglione, M. C. & Uplekar, M. WHO's new stop TB strategy. Lancet 367, 952-955 (2006).
82. Lienhardt, C., Vernon, A. & Raviglione, M. C. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med. 16, 186-193 (2010).
83. Ma, Z. et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100- 2109 (2010).
84. Boehme, C. C. et al. Rapid molecular detection of tuberculosis and rifampicin resistance. N. Engl. J. Med. 363, 1005-1015 (2010).
85. Wallis, R. S. et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375, 1920-1937 (2010).
86. Kaufmann, S. H. E., Hussey, G. & Lambert, P.-H. New vaccines for tuberculosis. Lancet 375, 2110-2119 (2010).
87. Stop TB Partnership and WHO. Global Plan to Stop TB, 2011-2015: Transforming the Fight Towards Elimination of Tuberculosis. (WHO, 2010).
88. Treatment Action Group. 2011 Report on Tuberculosis Research Funding Trends, 2005-2010. (Treatment Action Group, 2012).
89. Glaziou, P. et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull. World Health Organ. 89, 573-582 (2011).
90. World Health Organization. Global tuberculosis control: WHO Report 201(WHO, 2011).
91. Lönnroth, K. et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 375, 1814-1829 (2010).
92. Atun, R., Weil, D. E., Eang, M. T. & Mwakyusa, D. Health-system strengthening and tuberculosis control. Lancet 375, 2169-2178 (2010).
93. Lienhardt, C., Espinal, M., Maher, D., Pai, M. & Raviglione, M. What research is needed to stop TB? Introducing the TB Research Movement. PLoS Med. 8, e1001135 (2011).
94. Abu-Raddad, L. J. et al. Epidemiological benefits of more effective tuberculosis vaccines, drugs and diagnostics. Proc. Natl Acad. Sci. USA 106, 13980- 13985 (2009).
95. Stop TB Partnership and WHO. The International Roadmap for Tuberculosis Research - Towards a World Free of TB. (WHO, 2011).
96. Lienhardt, C. Why is research critical to stop tuberculosis? PLoS Med. community blog [online], http://blogs.plos.org/speakingofmedicine/2012/01/26/ why-is-research-critical-to-stop-tuberculosis (2012).
97. Lin, H., Ezzati, M. & Murray, M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 4, e142 (2007).
98. Jeon, C. Y. & Murray, M. B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 5, e152 (2008).
99. Lönnroth, K., Williams, B. G., Stadlin, S., Jaramillo, E. & Dye, C. Alcohol use as a risk factor for tuberculosis-a systematic review. BMC Public Health 8, 289 (2008).
100. Lönnroth, K., Jaramillo, E., Williams, B. G., Dye, C. & Raviglione, M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc. Sci. Med. 68, 2240-2246 (2009).
101. Getahun, H. & Raviglione, M. Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. Bull. World Health Organ. 89, 616-618 (2011).